Dr. Klaff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
800 SW 39th St
#110
Renton, WA 98057
Summary
- Dr. Leslie Klaff is an endocrinologist and is a Medical Director of Rainier Clinical Research Center, an independent research center in Renton WA. He received his medical degree from University of the Witwatersrand in 1971 and was in Academic and private Endocrine practice until 2007 when he entered full time research. The
center specializes in pharmaceutical and device testing for diabetes and metabolic disorders.
Retired Feb 2022
Education & Training
University of Cape TownPhD, 1983
University of the WitwatersrandClass of 1971
Certifications & Licensure
WA State Medical License 1984 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- Fellow (FACE) American Association of Clinical Endocrinology, 2003
- Fellow (FRCP) Edin Royal College of Physicians (Edinburgh), 1990
Publications & Presentations
PubMed
- 34 citationsImproved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT StudyHalis Kaan Akturk, Janet K. Snell-Bergeon, Amanda Rewers, Leslie J. Klaff, Bruce W. Bode
Diabetes Technology & Therapeutics. 2018-09-26 - 32 citationsA Prospective Multicenter Evaluation of the Accuracy and Safety of an Implanted Continuous Glucose Sensor: The PRECISION Study.Mark P. Christiansen, Leslie J. Klaff, Timothy S. Bailey, Ronald L. Brazg, Grace Carlson
Diabetes Technology & Therapeutics. 2019-05-07 - 10 citationsDasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial.Timothy S. Bailey, Julie Willard, Leslie J. Klaff, Jenine Y Stone, Anita E. Melgaard
Diabetes, Obesity & Metabolism. 2021-10-01
Press Mentions
Long-Term Efficacy and Safety of Ultra Rapid Lispro (URLi) in Adults with Type 1 Diabetes: The PRONTO-T1D ExtensionJanuary 17th, 2021
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
